Corona Remedies ipo date, Share Price Target Tomorrow, 2025, 2026, 2030
Corona Remedies is an Indian medicine company. It makes medicines for people in India. The company mainly focuses on long-term health needs like women’s health, heart and diabetes care, pain relief, and urology, and it offers more than 70 simple and useful medicine brands in these areas. It is one of the fastest-growing pharma companies in India and earns most of its sales from long-term treatments. It has over 2,600 medical representatives who share information with doctors across many states. The company also runs two modern factories in Bhayla (Gujarat) and Solan (Himachal Pradesh), which follow strict quality standards, and it has a strong R&D team that develops new and improved medicines.
- 1 What is the Corona Remedies Ltd IPO?
- 2 Corona Remedies IPO Details
- 3 Corona Remedies IPO Reservation
- 4 Corona Remedies Share Price Target Tomorrow (Listing day price)
- 5 Corona Remedies Share Price Target 2025
- 6 Corona Remedies share price Target 2026
- 7 Share price Target 2027
- 8 Share price Target 2028
- 9 Share price Target 2029
- 10 Corona Remedies share price Target 2030
- 11 Share price Target 2040
- 12 Share Price Target 2050
- 13 Should I buy Corona Remedies stock?
- 14 Corona Remedies earnings results (Financials)
- 15 Is Corona Remedies stock good to buy? (bull case & bear case)
- 16 Corona Remedies IPO Promoter Holding
- 17 Objects of the Issue (Corona Remedies IPO Objectives)
- 18 Corona Remedies ipo gmp
- 19 Conclusion
- 20 FAQs
What is the Corona Remedies Ltd IPO?
Corona Remedies was established in 2004 in Ahmedabad, Gujarat, and its founders are Kirtikumar Laxmidas Mehta and his sons Nirav Mehta and Ankur Mehta. It is an Indian medicine company that makes and sells branded tablets, syrups, capsules, and other products. The company mainly works in women’s health, heart and diabetes care, pain relief, urology, and other common health needs. It has modern factories in Gujarat and Himachal Pradesh, follows good-quality standards, and grows by adding new brands and products to its portfolio.
Corona Remedies IPO Details
| IPO Date | December 8, 2025 to December 10, 2025 |
| Listing Date | 11 December 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹1008 to ₹1062 per share |
| Minimum Investment | December 8, 2025, to December 10, 2025 |
| Lot Size | 14 Shares |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 6,11,60,088 shares |
| Share Holding Post Issue | 6,11,60,088 shares |
Corona Remedies IPO Reservation
| Investor Category | Shares Offered |
| QIB Shares Offered | Not less than 50% of the Net Offer |
| Retail Shares Offered | Not more than 35% of the Net Offer |
| NII Shares Offered | Not more than 15% of the Net Offer |
Corona Remedies has strong financials because it has very little debt, handles its money smoothly, and collects payments faster than before. Its sales and profits have grown well, and it is earning good returns from the money it invests in the business. Even though its stock price is high compared to its earnings, the company’s steady growth, better money control, and strong performance in the Indian market show that it is doing well and moving forward in a stable and healthy way.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
| Tomorrow | -48 | +174 |
It is an Indian medicine company started in 2004. It makes safe and good-quality branded medicines. The company helps people live better lives by providing effective medicines made with care. Its main goal is to provide affordable and reliable healthcare to people across India. Doctors regularly prescribe their medicines, and the company focuses on areas where patients need long-term treatment. In 2025, its share price target would be ₹1410, as per stock market analysts.
According to stock market analysts, its share price would be between ₹890 to ₹1410 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 890 | 1410 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| December | 890 | 1410 |
It mostly makes branded medicines; the products are sold under their own brand names. These are not simple generic medicines but branded ones that doctors know well and often suggest to patients. The company builds strong brands, focuses on quality, patient trust, and good doctor relationships. This helps patients easily recognise and trust the medicines they use. Strong brands help the company grow steadily, as doctors and patients keep choosing them for many years. Their branded products cover many important health needs. In 2026, its share price target would be ₹2300, as per stock market analysts.
According to stock market analysts, its share price would be between ₹1390 to ₹2300 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 1390 | 2300 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1390 | 1578 |
| February | 1578 | 1685 |
| March | 1611 | 1700 |
| April | 1652 | 1754 |
| May | 1684 | 1790 |
| June | 1700 | 1825 |
| July | 1725 | 1858 |
| August | 1754 | 1992 |
| September | 1784 | 2058 |
| October | 1880 | 2112 |
| November | 1965 | 2254 |
| December | 2025 | 2300 |
It makes medicines for many important health problems. Their biggest area is women’s health, including gynaecology and fertility care. They also produce medicines for heart problems, diabetes, pain relief, and urology. These problems affect many people and require regular treatment, which makes them very important. The company also works on general health needs like vitamins, nutrition, and digestion. The company helps doctors and patients with reliable medicines they can use daily. In 2027, its share price target would be ₹3015, as per stock market analysts.
According to stock market analysts, its share price would be between ₹2224 to ₹3015 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 2224 | 3015 |
The company focuses mainly on long-term and chronic diseases, which helps it grow steadily. Chronic diseases need continuous treatment, so patients rely on their medicines regularly. This helps the company build strong, long-lasting relationships with doctors and patients. The company makes sure its products stay useful for many years. Health areas like heart care, diabetes, women’s health, and pain management help the company grow in a stable way and meet the country’s long-term healthcare needs. In 2028, its share price target would be ₹3960, as per stock market analysts.
According to stock market analysts, its share price would be between ₹2920 to ₹3960 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 2920 | 3960 |
It has two modern factories in Bhayla, Gujarat, and Solan, Himachal Pradesh. These factories use advanced machines to make medicines safely and properly. They follow strict quality rules to ensure every product meets high standards. The company pays attention to cleanliness, safety, and accuracy in every step of the manufacturing process. Their plants can produce tablets, capsules, liquids, and more. The company can make large amounts of high-quality medicines to meet India’s growing demand. In 2029, its share price target would be ₹4430, as per stock market analysts.
According to stock market analysts, its share price would be between ₹3880 to ₹4430 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 3880 | 4430 |
It also has a strong research and development (R&D) team that works on creating new medicines and improving old ones. Their research centres meet government standards and focus on studying patient needs and new medical trends. The R&D team develops better formulas, new packaging, and improved ways to deliver medicines. This helps the company stay updated with modern science and offer advanced products. Innovation is very important for it, as it helps them make unique and helpful medicines that stand out in the market. In 2030, its share price target would be ₹5517, as per stock market analysts.
According to stock market analysts, its share price would be between ₹4350 to ₹5517 in 2030.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 4350 | 5517 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 4350 | 4584 |
| February | 4387 | 4612 |
| March | 4424 | 4774 |
| April | 4556 | 4810 |
| May | 4587 | 4857 |
| June | 4735 | 4890 |
| July | 4515 | 4910 |
| August | 4789 | 4974 |
| September | 4868 | 5025 |
| October | 4942 | 5225 |
| November | 5024 | 5368 |
| December | 5254 | 5517 |
It has a strong presence across India with over 2,600 medical representatives. These representatives visit doctors, explain product benefits, and make sure pharmacies always have the medicines in stock. Their wide network ensures fast and reliable supply in many states. This strong distribution system is very important in the medicine industry, and the company has built it over many years. Because of this network, their branded medicines reach patients in both big cities and small towns. In 2040, its share price target would be ₹12200, as per stock market analysts.
According to stock market analysts, its share price would be between ₹10857 to ₹12200 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 10857 | 12200 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 10857 | 11051 |
| February | 10930 | 11174 |
| March | 10984 | 11253 |
| April | 11087 | 11335 |
| May | 11120 | 11557 |
| June | 11256 | 11662 |
| July | 11335 | 11752 |
| August | 11512 | 11852 |
| September | 11625 | 11930 |
| October | 11841 | 12078 |
| November | 11882 | 12157 |
| December | 11978 | 12200 |
It is a fast-growing Indian pharmaceutical company that combines strong research, reliable manufacturing, and a wide doctor network to offer high-quality medicines. The company focuses on long-term health needs, branded products, and strict quality standards, which makes it trusted by many doctors. It continues to grow by adding new brands, improving factories, and investing in science and research. With clear goals and strong values, it keeps improving and serving patients across India. Its long-term approach brings trust, stability, and steady growth in everything it does. In 2050, its share price target would be ₹22790, as per stock market analysts.
According to stock market analysts, its share price would be between ₹20217 to ₹22790 in 2050.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 20217 | 22790 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 20217 | 20451 |
| February | 20421 | 20662 |
| March | 20520 | 20750 |
| April | 20662 | 20884 |
| May | 20721 | 20984 |
| June | 20820 | 21120 |
| July | 20920 | 21441 |
| August | 21240 | 21750 |
| September | 21542 | 21985 |
| October | 21754 | 22254 |
| November | 21985 | 22451 |
| December | 22251 | 22790 |
Should I buy Corona Remedies stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 890 | 1410 |
| 2026 | 1390 | 2300 |
| 2027 | 2224 | 3015 |
| 2028 | 2920 | 3960 |
| 2029 | 3880 | 4430 |
| 2030 | 4350 | 5517 |
| 2040 | 10857 | 12200 |
| 2050 | 20217 | 22790 |
It could be a good option for long-term investment because it makes steady profits and has many trusted branded medicines. It focuses on important health areas like women’s health, heart and diabetes care, pain relief, and urology. The company has strong factories, a large distribution network, and low debt, which shows it is run well. But there are some risks, such as competition, government rules, and dependence mostly on the Indian market. If you are okay with some risk and want long-term growth, it can be a good stock.
Corona Remedies earnings results (Financials)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
| Sales + | 509 | 601 | 576 | 617 | 884 |
| Expenses + | 444 | 509 | 471 | 600 | 756 |
| Operating Profit | 66 | 93 | 105 | 18 | 128 |
| OPM % | 13% | 15% | 18% | 3% | 14% |
| Other Income + | 3 | 3 | 5 | 7 | 7 |
| Interest | 1 | 2 | 2 | 5 | 4 |
| Depreciation | 14 | 16 | 16 | 20 | 20 |
| Profit before tax | 54 | 77 | 92 | -1 | 111 |
| Tax % | 35% | 24% | 24% | -49% | 23% |
| Net Profit + | 35 | 59 | 70 | -0 | 85 |
| EPS in Rs | — | — | — | — | — |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Is Corona Remedies stock good to buy? (bull case & bear case)
Bull Case:
- In FY 2025, Corona Remedies earned about 1196.42 crore in revenue, up from 1014.47 crore in FY 2024, showing strong growth in sales.
- Its profit after tax increased to around 149.43 crore in FY 2025 from 90.50 crore in FY 2024, meaning the company is making more money.
- The EBITDA increased from about 161.19 crore in FY 2024 to 245.91 crore in FY 2025, indicating it is controlling costs and operating efficiently.
- The company has 71 brands across many health areas, helping it avoid dependence on just a few products.
- It has two modern factories in Gujarat and Himachal Pradesh, and a wide network of doctors and distributors. It supplies medicines across India reliably.
Bear Case:
- Most of the revenue comes from a few key therapy areas and main brands, so if demand drops or competition increases, overall income could fall.
- The company mainly works in India, so any slowdown in the economy or new government rules could hurt business.
- The pharma business has risks like new regulations, pricing pressure, competition from cheaper medicines, or supply and manufacturing problems, which could reduce profits.
Corona Remedies IPO Promoter Holding
The company’s promoters are Dr Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta and Ankur Kirtikumar Mehta.
| Promoter Holding Pre-Issue | 72.50% |
| Promoter Holding Post Issue | — |
Objects of the Issue (Corona Remedies IPO Objectives)
- It plans to use ₹50 crore from the IPO to expand its factories and research facilities so it can make more medicines and develop new products.
- It will use ₹40 crore from the IPO to pay off or reduce existing debt, which will lower interest costs and make the company financially stronger.
- It plans to use ₹30 crore from the IPO to buy new machines and equipment to improve production efficiency.
- It plans to use ₹25 crore from the IPO for marketing and promotion to make the brand more popular and visible to doctors and patients.
- The remaining funds will be used for general business needs, such as daily operations and working capital to run the company smoothly.
Corona Remedies ipo gmp
| GMP Date | IPO Price | GMP | Sub2 Sauda Rate | Estimated Listing Price | Estimated Profit* | Last Updated |
| 04-12-2025 | 1062.00 | ₹320 | 3400/47600 | ₹1382 (30.13%) | ₹4480 | 4-Dec-2025 10:31 |
Conclusion
It is a growing Indian medicine company that makes safe and trusted branded medicines for important health needs like women’s health, heart and diabetes care, pain relief, and urology. It has over 70 popular brands, two modern factories in Gujarat and Himachal Pradesh, and a strong research team that works on creating new and better medicines. The company also has a large network of more than 2,600 medical representatives who make sure its medicines reach doctors and patients all over India.
